UNSPSC 51372018: Nalfurafine

This classification denotes an opioid receptor agonist with the molecular formula C28H32N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XC41AVD567, chemically known as (e)-n-(17-(cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6beta-yl)-3-(furan-3-yl)-n-methylprop-2-enamide but generally known as nalfurafine, which bears US NIH Compound Identifier 6445230. European Medicines Agency schedules Nalfurafine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25222.

UNSPSC 51372018 Nalfurafine is a Commodity code that describes pharmaceutical products, but recent state and local solicitations tagged under this code show little alignment with nalfurafine specifically. Instead, the opportunities present a broader pharmaceutical and drug-supply procurement landscape spanning naloxone distribution, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals through cooperative purchasing vehicles. State and local governments buying under this code are acquiring emergency response medications, prescription fulfillment infrastructure, and OTC products to support community health, pharmacy benefit management, and inter-jurisdictional cooperative procurement objectives. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances, indicating that pharmaceutical procurement spans health emergency response, state pharmacy benefits administration, and cooperative procurement frameworks designed to leverage multi-jurisdiction volume.

Geographic activity centers on Florida, Texas, and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) procurement extending to Oregon and other participating jurisdictions. Representative recent opportunities include Seminole County, Florida's IFB60459723LAS, an IFB posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline and quarterly deliveries; the Texas Health and Human Services Commission's RFI HHS0017013, posted April 3, 2026, exploring vendor capabilities for direct-to-manufacturer prescription programs; and MMCAP's RFP S1070000015802, posted January 20, 2026, with a March 26, 2026 deadline, establishing multiple contracts for generic multi-source pharmaceuticals and OTC products across participating states with awards effective July 1, 2026. The MMCAP procurement emphasizes price competitiveness (75 percent evaluation weight), compliance with cGMP and DSCSA, and distribution through three authorized wholesalers, with performance penalties for late reporting or missed onboarding timelines.